Get the Stockscreener App
1.14
2.56%
-0.03
Metagenomi Therapeutics Inc stock is traded at $1.14, with a volume of 239.20K.
It is down -2.56% in the last 24 hours and down -12.98% over the past month.
Metagenomi Therapeutics Inc is an vivo genome editing company capitalizing on its proprietary technologies to create curative genetic medicines for patients. The company leverages machine learning and artificial intelligence to enhance its signature gene editing systems. MGX-001 is its, wholly-owned development program in hemophilia A, where the company have demonstrated targeted genome editing and durable gene expression from a one-time treatment in non-human primates (NHPs) and an overall profile potentially competitive with best-in-class treatment options. MGX-001 is designed to provide curative, life-long protection from bleeding events and joint damage in adults and children with hemophilia A from a single administration.
See More
Previous Close:
$1.17
Open:
$1.15
24h Volume:
239.20K
Relative Volume:
1.29
Market Cap:
$42.92M
Revenue:
$25.21M
Net Income/Loss:
$-87.87M
P/E Ratio:
-0.4837
EPS:
-2.357
Net Cash Flow:
$-89.47M
1W Performance:
-7.32%
1M Performance:
-12.98%
6M Performance:
-33.33%
1Y Performance:
-20.83%
1-Day Range:
$1.13
$1.17
1-Week Range:
$1.13
$1.28
52-Week Range:
$1.13
$3.95
Metagenomi Therapeutics Inc Stock (MGX) Company Profile
Name
Metagenomi Therapeutics Inc
Sector
Industry
Phone
(510) 871-4880
Address
5959 HORTON STREET, EMERYVILLE
Compare MGX vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MGX
Metagenomi Therapeutics Inc
|
1.14 | 44.05M | 25.21M | -87.87M | -89.47M | -2.357 |
VRTX
Vertex Pharmaceuticals Inc
|
453.17 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.73 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
878.49 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
281.90 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
156.58 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Metagenomi Therapeutics Inc Stock (MGX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-07-24 | Initiated | H.C. Wainwright | Buy |
| May-02-24 | Downgrade | JP Morgan | Overweight → Neutral |
| Mar-05-24 | Initiated | BMO Capital Markets | Outperform |
| Mar-05-24 | Initiated | Chardan Capital Markets | Buy |
| Mar-05-24 | Initiated | JP Morgan | Overweight |
| Mar-05-24 | Initiated | Jefferies | Buy |
| Mar-05-24 | Initiated | TD Cowen | Outperform |
| Mar-05-24 | Initiated | Wells Fargo | Overweight |
View All
Metagenomi Therapeutics Inc Stock (MGX) Latest News
Metagenomi Therapeutics (MGX) director awarded 17,400 stock options at $1.23 - Stock Titan
Metagenomi Therapeutics (MGX) director awarded options on 21,000 shares - Stock Titan
Metagenomi Therapeutics (MGX) director receives 21,000-share stock option grant at $1.23 - Stock Titan
Metagenomi (NASDAQ: MGX) director receives 21,000 stock options at $1.23 strike - Stock Titan
Metagenomi CFO Pamela Wapnick sells $3,746 of company stock - Investing.com UK
Metagenomi CEO Jian Irish sells $4,854 in company stock - Investing.com UK
Metagenomi general counsel Wein sells $724 in common stock - Investing.com UK
Metagenomi CFO Pamela Wapnick sells $3,746 of company stock By Investing.com - Investing.com Australia
[Form 4] Metagenomi Therapeutics, Inc. Insider Trading Activity - Stock Titan
Tax-driven sale as Metagenomi (MGX) director Irish reports 3,737 shares sold - Stock Titan
Metagenomi Announces Board Changes and Shareholder Meeting Results - TipRanks
Metagenomi Therapeutics, Inc. Announces Resignation of Brian C. Thomas, Ph.D. as A Member of the Board, Effective as of June 9, 2026 - marketscreener.com
Brian C. Thomas resigns from Metagenomi board effective June 9, 2026 - TradingView
Metagenomi (NASDAQ: MGX) director exits as shareholders back board - Stock Titan
MGX: Directors and auditor were approved, with no stockholder questions or new nominations - TradingView
MGX: Directors elected, auditor ratified, and all proposals approved with no shareholder questions - TradingView
Did Metagenomi Therapeutics, Inc. Insiders Breach their Fiduciary Duties to Shareholders? - PR Newswire
Metagenomi Therapeutics (MGX) Slides 2.86% as Stock Tests Key Support LevelsSweep Order Flow - newsline.com
MGX Q1 2026 Earnings: Losses Widen Beyond Expectations as Pre-Revenue Biotech Focuses on PipelineEarnings Forecast Report - thelegaladvocate.com
Metagenomi Therapeutics, Inc. to Present at the Jefferies Global Healthcare Conference - The Manila Times
MGX Q1 2026 Earnings: EPS Misses Estimates as Pre-Revenue Biotech Advances PipelineEPS Growth Report - The Legal Advocate
MGX Q1 2026 Earnings: Missed Expectations as Pre-Revenue Biotech Advances Gene Editing PipelineEarnings Cycle Outlook - Newser
PRN_FinancialWrapper - FinancialContent
Number of shareholders of Metagenomi Therapeutics, Inc. – NASDAQ:MGX - TradingView
Metagenomi Therapeutics (MGX) price target decreased by 10.71% to 8.50 - MSN
Metagenomi Therapeutics, Inc. (NASDAQ:MGX) Just Reported And Analysts Have Been Cutting Their Estimates - Yahoo Finance
Analysts Have Lowered Expectations For Metagenomi Therapeutics, Inc. (NASDAQ:MGX) After Its Latest Results - simplywall.st
Metagenomi Therapeutics (MGX) reports Q1 loss, misses revenue estimates - MSN
Wells Fargo Maintains Metagenomi Therapeutics(MGX.US) With Buy Rating, Cuts Target Price to $9 - Moomoo
Metagenomi Therapeutics (MGX) Reports Q1 Loss, Misses Revenue Estimates - Yahoo Finance
MSN Money - MSN
Metagenomi Highlights Q1 Progress on MGX-001 Gene Therapy - TipRanks
Metagenomi Therapeutics Reports Business Updates and First Quarter 2026 Financial Results - The Manila Times
Metagenomi Therapeutics: Q1 Earnings Snapshot - kare11.com
Metagenomi Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
[10-Q] Metagenomi Therapeutics, Inc. Quarterly Earnings Report - Stock Titan
Metagenomi (NASDAQ: MGX) details Q1 2026 loss, cash runway and MGX-001 IND plans - Stock Titan
Metagenomi gene edit for hemophilia A targets 2027 human trials - Stock Titan
MGX Stock Price, Quote & Chart | METAGENOMI THERAPEUTICS INC (NASDAQ:MGX) - ChartMill
Hemophilia Clinical Trial Pipeline Gains Momentum: 50+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight - GlobeNewswire Inc.
SEC Form DEF 14A filed by Metagenomi Therapeutics Inc. - Quantisnow
[DEF 14A] Metagenomi Therapeutics, Inc. Definitive Proxy Statement - Stock Titan
MGX Price Today: Metagenomi Therapeutics, Inc. Stock Price, Quote & Chart | MEXC - MEXC Exchange
Metagenomi Therapeutics (MGX) Stock: Sentiment Analysis (Weakens) 2026-04-22Large Cap Trends - Xã Thanh Hà
MGX Financials: Income Statement, Balance Sheet & Cash Flow | Metagenomi Therapeutics, Inc - Stock Titan
A smaller gene editor cut Atxn2 protein 64% in mice, Metagenomi says - Stock Titan
Metagenomi reports compact gene editing tool in Nature journal - Investing.com
What is the valuation of Metagenomi Therapeutics (MGX) Stock | Price at $1.39, Up 0.72%Stock Surge Alerts - newsline.com
MGX: Metagenomi Therapeutics, Inc.Detailed Earnings Estimates - Zacks Investment Research
Metagenomi Can’t Ax IPO Investor Suit Over Moderna Partnership - Bloomberg Law News
Metagenomi Therapeutics Inc Stock (MGX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Metagenomi Therapeutics Inc Stock (MGX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Irish Jian | See Remarks |
Jun 05 '26 |
Sale |
1.30 |
3,737 |
4,854 |
377,533 |
| Wein Matthew | See Remarks |
Jun 05 '26 |
Sale |
1.30 |
558 |
725 |
126,491 |
| Wapnick Pamela | Chief Financial Officer |
Mar 05 '26 |
Sale |
1.60 |
1,581 |
2,530 |
187,375 |
| Wein Matthew | See Remarks |
Mar 05 '26 |
Sale |
1.60 |
482 |
771 |
114,549 |
| Irish Jian | Chief Executive Officer |
Mar 05 '26 |
Sale |
1.60 |
1,607 |
2,571 |
333,770 |
| Thomas Brian C. | Director |
Dec 05 '25 |
Sale |
1.77 |
3,830 |
6,786 |
2,510,960 |
| Wein Matthew | See Remarks |
Dec 05 '25 |
Sale |
1.77 |
199 |
353 |
115,031 |
| Wapnick Pamela | Chief Financial Officer |
Dec 05 '25 |
Sale |
1.77 |
1,576 |
2,793 |
188,956 |
| Irish Jian | Chief Executive Officer |
Dec 05 '25 |
Sale |
1.77 |
1,602 |
2,839 |
563,839 |
| Thomas Brian C. | Director |
Sep 05 '25 |
Sale |
1.81 |
2,701 |
4,889 |
2,514,790 |
1.27%
1.43%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):